Craig Rohan, MD
Dermatology · Wright Patterson Afb, OHNPI 1366414591
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by UCB SA at 52.1% of the total. 2025 is the largest year on record at $8,017, more than ten times the $75 reported in 2019.
Across 26 payments — averaging $518.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$7K
- Boehringer Ingelheim$5K
- Novartis$1K
- AbbVie$125
- Janssen Research & Development, LLC$52
- UCB, Inc.$45
- plus $49 from 2 others
Across 270 payments — averaging $3356.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$189K
- AbbVie$187K
- Janssen Research & Development, LLC$161K
- Eli Lilly$116K
- Incyte Corporation$76K
- E.r. Squibb & Sons, L.L.C.$45K
- plus $133K from 6 others
What the payments were for
- Consulting fees$5,14038%
- Speaking & faculty fees$5,48241%
- Travel & lodging$2,01015%
- Food & beverage$8436%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 13 | $7,014 |
| Boehringer Ingelheim | 1 | $5,140 |
| Novartis | 5 | $1,050 |
| AbbVie | 3 | $125 |
| Janssen Research & Development, LLC | 1 | $52 |
| UCB, Inc. | 1 | $45 |
| Janssen Scientific Affairs, LLC | 1 | $36 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,475 in reported general payments places this provider in the 85th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 18 | $386,973 |
| Dupixent PenDupilumab | 95 | $359,896 |
| OtezlaApremilast | 48 | $273,650 |
| Cosentyx Unoready PenSecukinumab | 15 | $173,038 |
| RemicadeInfliximab | 17 | $112,470 |
| XolairOmalizumab | 23 | $57,075 |
| Dupixent SyringeDupilumab | 11 | $38,487 |
| Clobetasol Propionate | 198 | $8,685 |
| Ketoconazole | 287 | $4,860 |
| Mometasone Furoate | 253 | $4,721 |
| Fluocinonide | 74 | $3,811 |
| Dapsone | 29 | $3,752 |
| CholestyramineCholestyramine (With Sugar) | 58 | $3,486 |
| Doxycycline Hyclate | 81 | $3,434 |
| Fluorouracil | 27 | $3,014 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Wright Patterson Afb
- Matthew ZirwasBexley$3.3M
- George DrewMarion$1.9M
- Rocco SerraoDayton$1.7M
- James LibeccoFairlawn$1.1M
- Pranav ShethWest Chester$978K
- Dawn MerrittAthens$844K
- Neil KormanCleveland$824K
- Joshua GrosshandlerWesterville$479K
- Lorie GottwaldToledo$460K
- Gregory DelostMayfield Heights$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.